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Abstract
Background There is growing interest internationally in
linking reimbursement decisions with recommendations for
further research. In the UK, the National Institute for
Health and Clinical Excellence (NICE) can issue guidance
to approve the routine use of a health intervention, reject
routine use or recommend use within a research pro-
gramme. These latter recommendations have restricted use
to ‘only in research’ (OIR) or have recommended further
research alongside routine use (‘approval with research’ or
AWR). However, it is not currently clear when such rec-
ommendations are likely to be made.
Objectives This study aims to identify NICE technology
appraisals where OIR or AWR recommendations were
made and to examine the key considerations that led to
those decisions.
Methods Draft and final guidance including OIR/AWR
recommendations were identified. The documents were
reviewed to establish the characteristics of the technology
appraisal, the cost effectiveness of the technologies, the
key considerations that led to the recommendations and the
types of research required.
Results In total, 29 final and 31 draft guidance docu-
ments included OIR/AWR recommendations up to
January 2010. Overall, 86 % of final guidance included
OIR recommendations. Of these, the majority were for
technologies considered to be cost ineffective (83 %)
and the majority of final guidance (66 %) specified the
need for further evidence on relative effectiveness.
The use of OIR/AWR recommendations is decreasing
over time and they have rarely been used in apprais-
als conducted through the single technology appraisal
process.
Conclusion NICE has used its ability to recommend
technologies within research programmes, although pre-
dominantly within the multiple technology appraisal
process. OIR recommendations have been most fre-
quently issued for technologies considered cost ineffec-
tive and the most frequently cited consideration is
uncertainty related to relative effectiveness. Key consid-
erations cited for most AWR recommendations and some
OIR recommendations included a need for further evi-
dence on long-term outcomes and adverse effects of
treatment.
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Key Points for Decision Makers
• The National Institute for Health and Clinical
Excellence (NICE) has issued recommendations for
the use of technologies within the context of evidence
development since it was first established
• The guidance referring to evidence development
usually takes the form of recommending a technology
is used ‘only in’ the context of research, but recom-
mendations of evidence collection alongside approval
have also been issued
• The incremental cost-effectiveness ratios (ICERs) of
these technologies were usually higher than the
standard threshold range and there was usually
uncertainty around the magnitude of clinical effect
• The use of ‘only in research’ and ‘approval with
research’ recommendations has decreased over recent
years and is rare for technologies appraised through
the single technology appraisal process
• A transparent and systematic framework for the use
of recommendations including evidence development
would be beneficial
1 Introduction
There has been growing interest in the inclusion of formal
requirements for the collection of further evidence within
reimbursement decisions as part of the technology approval
processes undertaken by healthcare agencies [1–7]. A
recent review found that five countries have implemented
‘coverage with evidence development’ schemes: Australia,
France, Sweden, the UK and the USA [2]. In the UK, most
national decisions about which health technologies should
be used routinely in the NHS are made by the National
Institute for Health and Clinical Excellence (NICE). In
addition to recommendations of whether a technology
should be approved for routine use or not, it has also been
established that NICE has the option of recommending the
use of a technology in the context of evidence develop-
ment, including the collection of data within registries,
prospective cohort studies and pragmatic randomized
trials [8].
A range of terminology is used within agencies and the
literature to refer to these types of recommendations that
link reimbursement decisions with requests for further
evidence development. In addition, the recommendations
can be implemented in different ways. Two distinct types
of recommendations directly incorporating evidence
development can be termed as recommendations of use
‘only in research’ (OIR) or ‘approval with research’
(AWR). The distinction between these two forms of
guidance is principally the extent of coverage that each
confers: whether all patients taking the technology must
participate in the research programme or if non-participants
can also routinely access the technology providing the
research gets conducted. There is, however, a lack of
consensus on the circumstances under which such schemes
should be recommended. NICE provides its Appraisal
Committees with general guidance on the health technol-
ogy assessment (HTA) methodologies and social value
judgements it considers to be most appropriate for the
formulation of NICE guidance [9–11]. These documents
include guidance on the assessment of effectiveness, cost
effectiveness and other considerations. With regard to
research recommendations, NICE states that its:
advisory bodies may sometimes recommend that an
intervention is used only within a research pro-
gramme. They should consider whether the inter-
vention is reasonably likely to benefit patients and the
public, how easily the research can be set up or
whether it is already planned or in progress, how
likely the research is to provide further evidence, and
whether the research is good value for money. [10]
The documents do not distinguish explicitly between
alternative types of research recommendations, and do not
describe any formal mechanisms for linking the decisions
to funding for the research.
Other recent developments include linking reimburse-
ment with evidence of outcomes generated after approval.
For example, in 2009 NICE established a formal process
for the consideration of ‘patient access schemes’ (PASs),
which are aimed at enabling patients to gain access to high-
cost drugs by improving their cost effectiveness [12].
Whilst this formal process is new, ‘access’ or ‘risk-sharing’
schemes have previously been adopted by the Department
of Health in the UK, for example the risk-sharing scheme
for interferon beta [13]. Importantly, these new PASs do
not necessarily require the collection of additional evi-
dence; rather they could include a simple price discount or
other cost reduction. It is the requirement for evidence
collection that characterizes the difference between OIR/
AWR recommendations and the broader range of condi-
tional reimbursement recommendations.
There are pressures on reimbursement and HTA agen-
cies to make rapid and clear decisions about approval and
reimbursement when a technology is first launched within
the respective healthcare system. In response to such
pressures in the UK, NICE responded by establishing a
faster process for appraisal, the single technology appraisal
(STA) process, to issue guidance closer to the time of
marketing authorization. Recommendations including
requirements for evidence development may be particu-
larly valuable for technologies such as those appraised
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earlier in the product history, as the evidence base will be
least mature and there may be substantial uncertainty in
cost effectiveness. However, it is unclear what impact the
introduction of the STA process at NICE has had on the use
of OIR/AWR recommendations.
Previous research has identified that NICE in the UK
uses some forms of recommendations with evidence
development [14–16]. NICE has itself considered some
potential issues that could be taken into account when
formulating these recommendations through its ‘Citizens
Council’ [17]. However, the extent to which the stated
criteria employed by NICE have been considered in the
formulation of guidance has not been previously examined
and no clear guidance has been issued on when NICE
advisory bodies should consider recommending research
rather than standard ‘accept’ or ‘reject’ decisions. The
primary aim of this review was to identify where OIR/
AWR recommendations were made or considered in the
development of NICE guidance. Secondary aims were to
identify the considerations that led to the recommendations
for further research, to identify any common characteristics
in appraisals including OIR/AWR recommendations and to
assess the implementation of the OIR/AWR recommen-
dations based on reviews of published guidance. This
review forms part of a larger piece of research to establish
an improved framework for formulating approval and
research recommendations under uncertainty at NICE
[18, 19].
2 Methods
A systematic review of NICE technology appraisal (TA)
documents was conducted. The aim of the systematic
review was to identify those pieces of guidance where OIR
or AWR recommendations were proposed.
2.1 Inclusion and Exclusion Criteria
All NICE TA guidance up to January 2010 was considered
for inclusion in the review. This included all draft and final
guidance documents. The document containing the Com-
mittee’s intended final recommendations is the ‘Final
Appraisal Determination’ or FAD. These are made publicly
available and can be appealed by specific stakeholders
before becoming final guidance to the NHS. In 2002, the
NICE process was amended to also publish draft guidance
documents in the form of ‘Appraisal Consultation Docu-
ments’ or ACDs for public consultation. Where changes in
guidance are made following consultation or appeal, there
may be multiple ACDs or FADs related to a single
appraisal; all versions of the ACDs and FADs were
reviewed. The document published as final formal
guidance to the NHS is referred to here as the final guid-
ance document.
NICE guidance documents are published in a standard-
ized format with the guidance to the NHS presented in
section 1. The rest of the guidance document provides an
overview of the evidence, an explanation of how the evi-
dence was interpreted by the Committee, and additional
information to assist the implementation of the guidance.
Each guidance document usually includes a section
detailing key evidence gaps or suggestions for further
related research. The guidance is not conditional upon the
fulfilment of these recommendations and they do not form
part of the mandatory guidance to the NHS, and are
therefore not defined as OIR/AWR recommendations for
this review. For inclusion, the guidance documents (draft
or final) had to refer to requested, ongoing or planned
research in the ‘Guidance’ section (section 1) of the doc-
uments. The research recommendations could be framed
either as OIR or AWR based on the following definitions:
• OIR: a recommendation stating that the technology
should not be used routinely and advocating that further
research should be conducted in the Guidance section.
• AWR: a recommendation stating that the technology
should be used routinely and advocating that further
research should be conducted in the Guidance section.
Only documents that have been made publicly available
were included; specifically ACDs for TAs 1–43, except 32,
were not made publicly available. Documents that have
been publicly released but later removed from the NICE
website were included in the review (for example, guidance
that has been replaced by a subsequent review), and have
been obtained directly from NICE where appropriate. Draft
recommendations that request further clarification or
analysis from the sponsor of the technology (sometimes
referred to as ‘minded no’ recommendations in the STA
process) are excluded as they require the reanalysis of
existing data rather than additional data collection. Guid-
ance including PASs could be categorized as OIR/AWR
providing that the guidance was conditional on the access
scheme, and that the scheme contained a requirement for
further research or the collection of further data. The
documents containing OIR/AWR recommendations were
cross-checked with a review of OIR recommendations
compiled by NICE to check for potential omissions [16].
2.2 Data Extraction and Analysis
Data from each document that included OIR and/or AWR
recommendations were extracted using a template devel-
oped specifically for the project. Where recommendations
changed between draft and final guidance, explanations for
the change were reviewed and assessed. Extracted data
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included: background details on the appraisal and the
technology under consideration, and estimates of cost
effectiveness. Also included in the data extraction template
was a categorization of potential issues that could have led
to the issue of OIR/AWR recommendations. Thematic
content analysis of the ‘Committee considerations’ section
of the guidance documents was conducted to extract the
considerations leading to the recommendations. An initial
categorization of themes was developed following a review
of the literature conducted in parallel as part of a wider
research project. This was amended following a review of a
sample of guidance documents. The guidance documents
were reviewed to identify the stated reasons for the OIR/
AWR recommendation and coded according to one or
more of the pre-determined categories. The focus was on
extracting the stated rationale for the guidance rather than
inferring what the Committee’s considerations could or
should have been. The specific items of data extracted are
reported in Table 1. Data were extracted by one reviewer
(JY) and a sample was cross-checked by another reviewer
(LL). The data were analysed to identify common char-
acteristics of appraisals that included OIR and/or AWR
recommendations, and to assess if there were differences
according to the type of recommendation (OIR or AWR).
Table 1 Data extracted
ACD Appraisal Consultation
Document, AWR approval with
research, FAD Final Appraisal
Determination, ICER
incremental cost-effectiveness
ratio, MTA multiple technology
appraisal, NICE National
Institute for Health and Clinical
Excellence, OIR only in
research, PAS patient access
scheme, STA single technology
appraisal




Appraisal process (STA or MTA)
Type of document (ACD or FAD)
Was the guidance an update to a previous appraisal?
Has the guidance been subsequently reviewed?
Technology and
condition
Prevalence and incidence of the condition
Total population size
Type of technology (pharmaceutical, device, diagnostic, other)
Guidance Type of recommendation (OIR or AWR)
Type of research recommended (experimental or observational)
Recommendations for subgroups and subgroup definitions
Was the guidance conditional on a PAS?
Cost effectiveness Sponsor and independent Assessment Group estimates:
the ICERs for the whole population and the OIR/AWR subgroup
the probability of the technology being cost effective at a £20,000 and a £30,000
per QALY gained threshold
The ICER (mean and/or range) reportedly judged by the NICE Appraisal
Committee to be the most plausible




relative clinical effectiveness (whole population)
relative clinical effectiveness (OIR/AWR subgroup)
natural history/progression of disease
long-term data
potential adverse effects
mechanism of treatment action
Cost effectiveness High uncertainty in cost-effectiveness estimates
The need for cost-effectiveness data with appropriate comparator
The need for more information on quality of life




Concern about potential budget impact
Concern about potential investment and irreversible costs
Concern about potential impact on ongoing research
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2.3 Examination of Updated Appraisals
Each piece of NICE guidance is considered for review after
a specified time from publication, usually after 3 years.
Those OIR/AWR recommendations that have been
reviewed by a later appraisal were identified. In order to
determine if the OIR/AWR recommendation had been
implemented, appraisals reviewing previous guidance were
examined for new evidence submitted since the original
appraisal specifically relating to the OIR/AWR recom-
mendation. Details of changes to the recommendations in
the guidance were also recorded.
3 Results
3.1 Characteristics of Appraisals with OIR and AWR
Recommendations
Of the 184 appraisals conducted up to January 2010, 40
included OIR/AWR recommendations in the draft and/or
final guidance. A list of all appraisals including OIR and
AWR recommendations is provided in the Supplementary
Table (Online Resource). Most guidance with OIR was not
specific about the research to be conducted and often
referred to the technology being ‘not recommended except
within clinical trials’ or being ‘recommended only within
clinical trials’. For example, guidance on mycophenolate
mofetil (MMF) for use in paediatric renal transplantation
stated: ‘‘The use of MMF in corticosteroid reduction or
withdrawal strategies for child and adolescent renal trans-
plant recipients is recommended only within the context of
randomised clinical trials’’ (TA99 [20]). There were some
exceptions to this. For example, the OIR guidance on
spinal cord stimulation provided more information on the
type of information the research should provide: ‘‘Spinal
cord stimulation is not recommended as a treatment option
for adults with chronic pain of ischaemic origin except in
the context of research as part of a clinical trial. Such
research should be designed to generate robust evidence
about the benefits of spinal cord stimulation (including pain
relief, functional outcomes and quality of life) compared
with standard care’’ (TA159 [21]).
AWR guidance was routinely more specific about the
type of evidence collected. A detailed AWR recommen-
dation was made for the use of inhaled insulin in a sub-
group of people: ‘‘Data on the use of inhaled insulin
according to this guidance should be collected as part of a
coordinated prospective observational study. The data
collected should include individual patient outcomes,
adverse events and measurements of lung function’’
(TA113 [22]). Similarly guidance on etanercept and inf-
liximab for the treatment of arthritis was prescriptive
regarding the data to be collected: ‘‘All clinicians pre-
scribing etanercept or infliximab should (with the patient’s
consent) register the patient with the Biologics Registry
established by the BSR [British Society for Rheumatology]
and forward information on dosage, outcome and toxicity
on a 6-monthly basis’’ (TA36 [23]).
Multiple ACDs were issued for some appraisals and the
31 ACDs containing OIR/AWR recommendations relate to
25 appraisals. Of the 31 ACDs, 26 (84 %) included OIR
recommendations and five (16 %) AWR recommendations.
All of the 29 FADs included in the review relate to a unique
appraisal and were all published as final guidance for the
appraised technology: 25 (86 %) were OIR recommenda-
tions and four (14 %) were AWR recommendations. OIR
recommendations were much more common than AWR
recommendations. Changes to the inclusion of OIR/AWR
recommendations between draft and final guidance were
more common than suggested by the summary numbers;
only 14 appraisals included OIR/AWR recommendations in
both draft and final guidance (ACDs were unavailable for a
further 12 appraisals). (See the Supplementary Table
[Online Resource] for further details.) In most cases, where
an OIR/AWR recommendation was removed after consul-
tation, the final guidance usually recommended the tech-
nology for all or a specific subgroup of patients.
A single piece of NICE guidance can include several
recommendations related to multiple technologies, multiple
indications or different settings for the use of the technol-
ogy. Over half of the OIR/AWR recommendations speci-
fied the need for further research in particular subgroups of
patients (52 % of OIR/AWR recommendations in final
guidance documents). In approximately a quarter of cases,
the OIR/AWR recommendations targeted a subset of the
technologies included in the appraisal.
Overall, 16 % of all appraisals included an OIR/AWR
recommendation in the final guidance. Table 2 shows a
recent decline in the frequency of guidance including
OIR/AWR recommendations. There were no apparent
differences in the decline between OIR and AWR recom-
mendations. No final guidance included OIR/AWR rec-
ommendations in 2007, which is the year following
the introduction of the STA process. Differences in the
frequency of OIR/AWR recommendations were observed
between the two NICE appraisal processes. Of appraisals
issued through the multiple technology appraisal (MTA)
process, OIR or AWR recommendations were included in
draft guidance of 23 appraisals and final guidance of 28
appraisals. These 28 TAs account for 19 % of all final
guidance issued within the MTA process. In the STA
process, only two ACDs and one piece of final guidance
contained OIR/AWR recommendations. This accounts for
just 2 % of all final guidance issued through the STA
process up to the time the review was conducted.
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The data were examined for differences in the use of
OIR/AWR recommendations according to general disease
area and the type of technology under appraisal. In absolute
terms, OIR/AWR recommendations were more common for
cancer treatments, accounting for over a third of all the
OIR/AWR recommendations in the final guidance, followed
by musculoskeletal conditions (n = 7), which accounted for
almost a quarter of cases identified. However, NICE has
appraised a large number of treatments for cancer: 28 % of
all published appraisals over the review period. Only 7 % of
all NICE TA guidance has related to musculoskeletal
conditions and so it appears that a disproportionate amount of
these have included OIR/AWR recommendations compared
with appraisals for other conditions.
Just over half of the appraisals with OIR/AWR recom-
mendations related to drugs (n = 16; 55 %). However,
taking into account the total number of TAs published
relating to drugs, the use of OIR/AWR recommendations
appears to be on average less common for these appraisals:
11 % of all drug appraisals within the period contained
OIR/AWR recommendations, compared with 47 % of all
guidance on therapeutic or surgical procedures and 27 % of
all guidance on devices.
3.2 Cost Effectiveness of Technologies with
OIR/AWR Recommendations
NICE requires all appraisals to include an assessment of
cost effectiveness usually framed as an incremental cost
per QALY. All appraisals that included an OIR/AWR
recommendation considered the cost effectiveness of the
technologies. Most of the guidance documents reported
several different estimates of incremental cost effective-
ness based on analyses submitted by different stakeholders,
relating to different uses of the technology or based on
different sets of assumptions or evidence. However, a
formal assessment of cost effectiveness was not always
conducted or reported in the ACD or FAD for the use of the
technology specified in the OIR/AWR recommendation.
Table 3 shows the base-case incremental cost-effectiveness
ratios (ICERs) for the overall population and for the spe-
cific OIR/AWR indication where this differs. Ideally, the
ICER considered most plausible by the Appraisal Com-
mittee after reviewing the evidence would be taken to
Table 2 The number of OIR/AWR recommendations by year of
publication







OIR AWR OIR AWR
2000 NA NA 6 0 35 (17)
2001 NA NA 2 0 14 (14)
2002 4 2 6 0 26 (23)
2003 3 0 1 3 21 (19)
2004 2 0 1 0 8 (13)
2005 6 1 3 0 43 (7)
2006 5 1 3 1 21 (19)
2007 2 1 0 0 0 (21)
2008 4 0 2 0 6 (32)
2009 0 0 1 0 5 (19)
Total 26 5 25 4
Overall total 31 29 16 (184)
ACD Appraisal Consultation Document, AWR approval with research,
NA not applicable, OIR only in research
Table 3 ICERs of technologies with OIR/AWR recommendations (in FADs only) [n (%)]
Incremental cost per QALY OIR/AWR indication Total population
Committee’s preferred estimate AG/ERG’s estimate Committee’s preferred estimate AG/ERG’s estimate
OIR AWR OIR AWR OIR AWR OIR AWR
Not reported 22 (85) 1 (20) 20 (77) 1 (20) 17 (65) 2 (40) 9 (35) 1 (20)
Dominates 0 0 0 0 0 0 0 0
\£20,000 0 0 1 (4) 0 1 (4) 0 4 (15) 0
£20,000–30,000 0 2 (40) 0 1 (20) 1 (4) 1 (20) 3 (12) 0
[£30,000 3 (12) 2 (40) 4 (15) 2 (40) 4 (15) 2 (40) 7 (27) 3 (60)
Dominated 0 0 0 1 (20) 0 0 0 1 (20)
Othera 1 (4) 0 1 (4) 0 3 (12) 0 3 (12) 0
Totalb 26 (100) 5 (100) 26 (100) 5 (100) 26 (100) 5 (100) 26 (100) 5 (100)
a ICER was not framed in terms of a cost per QALY or the base case was presented as a range that could not be classified into the categories
b Total = 31 ICERs from 29 FADs (26 with OIR and 5 with AWR): ICERs were reported for two technologies each in TA36 and TA93
AG Assessment Group, AWR approval with research, ERG Evidence Review Group, FAD Final Appraisal Determination, ICER incremental cost-
effectiveness ratio, OIR only in research, TA technology appraisal
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reflect the NICE view of cost effectiveness. As this was not
always reported, the base-case estimate from the indepen-
dent Assessment Group is also reported in the table.
Most of the reported ICERs were higher than the
£20,000–30,000 threshold range employed by NICE. Only
guidance phrased as AWR reported ICERs within the
£20,000–30,000 threshold range for the AWR indication as
preferred by the Committee. The two ICERs reported as
above this range for AWR guidance and considered plau-
sible by the Committee related to two technologies
reviewed within one appraisal and were only marginally
above £30,000. In some cases, ICERs were reported but
were based on analyses that did not use the QALY as the
outcome measure. For example, TA5 on the use of liquid-
based cytology reported ICERs of £1,100 and £2,500 per
life-year gained depending upon the length of the screening
interval [24]. Where ICERs were not directly reported,
there was often an indication of whether the technology
was considered to be cost effective. For example, TA8 on
hearing aid technology stated that: ‘‘Whilst it is impossible,
on the basis of the present evidence, to estimate meaningful
cost-utility ratios … additional spending on this service, if
appropriately targeted, has the potential to be highly cost
effective.’’ [25]
3.3 Considerations Leading to OIR/AWR Guidance
The frequency of technologies considered cost effective by
the Appraisal Committee when used in the context of the
OIR/AWR recommendation is presented in Table 4. In
most cases (79 % of FADs with OIR/AWR recommenda-
tions), the technology was not cost effective and an OIR
recommendation was issued. There were only a couple of
cases where OIR recommendations were made for tech-
nologies considered likely to be cost effective based on the
accepted analyses. These appraisals (TA5 [24] and TA51
[26]) requested that pilot implementation programmes be
undertaken prior to the large-scale and routine introduction
of the technologies into the NHS. In the small number of
cases where AWR recommendations were issued, the
technologies were usually considered to be cost effective.
In the single exception, the ICER for the technology was
higher than, but close to the upper bound of, the usual
threshold range and reported to be in the range of
£27,000–35,000 per additional QALY gained (TA36 [23]).
Table 5 shows the stated rationale for issuing the OIR/
AWR recommendations. Of the pieces of final guidance
that did not explain the rationale for the OIR/AWR rec-
ommendation, three were issued prior to a section on the
Committee’s considerations being routinely included in the
documents (TA5, TA6, TA17). The OIR in the other
appraisal related to three specific subgroups of patients:
two were not referred to in the Committee’s considerations
at all and it was stated that there was ‘‘no clinical or
modelling evidence, or expert opinion’’ to support the use
of the technology in the third subgroup (TA75 [27]).
A need for further evidence on the relative effectiveness
of the intervention in the overall population or the OIR/
AWR subgroup was the most commonly cited reason for
issuing the OIR/AWR recommendation (Table 5). Several
Table 4 Type of recommendation and conclusion regarding cost
effectiveness (in FADs only) [n]
Conclusion OIR AWR Total
Considered cost effective 2 3 5
Not considered cost effective 23 1 24
Total 25 4 29
AWR approval with research, FAD Final Appraisal Determination,
OIR only in research
Table 5 Types of reasons for including research recommendations
within the guidance (n)
Reason for requesting further research ACDs Final
guidance
OIR AWR OIR AWR
None stated 1 0 4 0
Clinical effectiveness
Need for more evidence on relative
effectiveness
17 2 16 0
Need for data on relative
effectiveness in the target OIR
population
12 3 8 1
Need for long-term data 8 5 3 4
Need for information on adverse
effects
3 3 1 3
Need for data on natural history/
disease progression
1 1 0 0
Need for further evidence to support
mechanism of treatment action




10 3 6 0
Need for cost-effectiveness data with
an appropriate comparator
2 0 1 1
Need for more data on quality-of-life
impact
4 2 3 0
Need for more data on costs 1 0 1 0
Other uncertainties
Budget impact 0 0 0 0
Investment and reversal costs 0 0 0 0
Potential impact on ongoing research 0 0 0 0
Note that there may be multiple ACDs for each appraisal and that
there may be more than one stated rationale for requiring further
research
ACD Appraisal Consultation Document, AWR approval with research,
OIR only in research
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reasons were cited in support of most recommendations
and the need for further evidence on relative effectiveness,
either in the overall population or the OIR/AWR subgroup,
was cited in 19 (66 %) FADs identified in the review, and
most of these included OIR recommendations. Of those
citing a lack of sufficient evidence on relative effective-
ness, only one included an AWR recommendation (TA113
[22]). This appraisal noted a gap in the evidence on clinical
effectiveness for the highly selective subgroup of patients
targeted in the recommendations and that the cost-effec-
tiveness estimates were sensitive to these estimates. It
recommended that the data would be most appropriately
collected through a registry.
There was a greater range of considerations cited for
draft AWR recommendations than for the final guidance.
All final AWR guidance documents referred to the need for
long-term data, and most also referred to a need for addi-
tional data on adverse effects. These two considerations
were also referred to in a small number of OIR final
guidance documents. A need for longer-term data was also
frequently cited as a consideration leading to the OIR/
AWR guidance. Uncertainty in the cost-effectiveness
estimates was a common consideration; however, in all
cases this was coupled with a need for further clinical
evidence. No guidance (draft or final) cited concern about
investment and reversal costs as a rationale for OIR/AWR
recommendations. However, TA51 on computerized cog-
nitive behavioural therapy (CCBT) did suggest concerns
regarding the levels of training required for the imple-
mentation of a recommendation to routinely introduce
CCBT into the NHS: ‘‘Further information is required
about the extent of training needed and circumstances
under which different staff could provide support for users
of CCBT’’ (TA51 [26]). Concern about the budget impact
of introducing the technology or the potential impact on
ongoing research did not lead to the OIR/AWR recom-
mendation in any of the appraisals.
NICE routinely considers the list price of technologies
(e.g. as reported in the British National Formulary for
drugs) and possible changes in price over time are not
usually taken into account. However, a system for con-
sidering reductions in the costs of treatment through PASs
has been established. None of the OIR/AWR guidance
identified within the review included a PAS; however, one
appraisal that included an OIR recommendation at an
earlier stage of development later included a PAS (TA129).
This appraisal included an OIR recommendation in the
draft guidance and stated that the technology was not
recommended except for use in well-designed clinical
studies and that the Committee was not persuaded of its
cost effectiveness; however, this was subsequently amen-
ded to a ‘reject’ recommendation after concerns were
raised about whether the research would be conducted. The
final guidance approved the technology following the offer
of a PAS, which would reduce the cost of providing
treatment. The PAS was designed to offer a rebate to the
NHS when patients’ disease responds less than partially to
treatment; however, there was no formal requirement for
data analysis and reporting beyond the level of rebate and it
is therefore not categorized as an OIR recommendation
here. In another appraisal, the OIR recommendation was
revised to an approval after the Committee revised their
estimates of cost effectiveness based on discounted prices
of the technology along with further information on qual-
ity-of-life improvements (TA166).
Considerations around ethical implications and whether
uncertainties in the evidence base would resolve over time
were not explicitly stated as reasons for issuing OIR or
AWR recommendations. In addition, the relative costs and
benefits of conducting research were not reported as con-
siderations of the Committee when formulating its research
recommendations.
Most of the appraisals that required relative effective-
ness data recommended experimental research designs for
evidence collection (Table 6). Two appraisals that cited a
need for further evidence on relative effectiveness in the
final guidance recommended observational studies due to
anticipated difficulties in conducting randomized con-
trolled trials (RCTs) in the specific OIR patient population
(TA37) or indication (TA167). There were changes in the
recommended type of research between draft and final
guidance, which were mainly due to changes in the target
OIR/AWR population (e.g. TA68) or the recommendation
of a broader type of research (e.g. TA89).
3.4 Review of Updated Appraisals
Among the OIR/AWR recommendations in the final guid-
ance, ten were updated following a review, including two
that were incorporated into clinical guidelines (CGs).
Table 7 provides details of the appraisals, whether additional
evidence was provided and the change to the OIR/AWR
recommendation (new evidence for other recommendations
included within the guidance is not noted in the table).
Table 6 The type of research recommended [n (%)]
Research type ACDs Final guidance
OIR AWR OIR AWR
Experimental 20 (77) 1 (20) 14 (56) 0
Observational 1 (4) 4 (80) 3 (12) 4 (100)
Unclear (or both) 5 (19) 0 8 (32) 0
Total 26 (100) 5 (100) 25 (100) 4 (100)
ACD Appraisal Consultation Document, AWR approval with research,
OIR only in research
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In the majority of reviewed appraisals, new evidence
informing the OIR/AWR recommendation was available
for the review. In three cases, no new evidence was pro-
vided that was specific to the OIR/AWR indication. For the
review of TA6, no new RCT data were available for the
OIR recommendation, which was made more restrictive in
the review guidance. New evidence on clinical effective-
ness was not available for the review of TA33, and
although new data on adverse effects were provided, they
were considered inadequate and no change was made to the
OIR recommendation. The OIR recommendation was
removed from the review of TA37 despite a lack of new
evidence presented. In this case, there had been a reduction
in demand for the drug in this setting (it had since become
licensed and NICE approved for treatment of an earlier
stage of disease) and there were concerns about the feasi-
bility of future data collection.
4 Discussion
This review has found that NICE issued OIR/AWR rec-
ommendations in 16 % of its published TA guidance.
These recommendations have most frequently taken the
form of OIR; however, a handful of recommendations were
phrased as AWR. Proportionately more OIR/AWR rec-
ommendations were issued for appraisals of procedures and
devices than of pharmaceuticals. The most common reason
cited for OIR/AWR recommendations was uncertainty
regarding relative effectiveness, necessitating the need for
further evidence. Potential investment and reversal costs
have not explicitly led to OIR/AWR recommendations.
Some authors have suggested that, along with other
criteria, OIR should be used only when the expected net
benefit from the technology is likely to be positive [28].
This review has highlighted that the majority of OIR rec-
ommendations issued by NICE were for technologies
considered unlikely to be cost effective based on the evi-
dence available at the time of the appraisal. Arguably, for
an OIR recommendation to be of value to decision makers,
it should have the potential to reverse the decision rejecting
the claim for reimbursement. None of the guidance iden-
tified included an explicit consideration of the likelihood of
the technology being cost effective based on the further
evidence within the rationale for the OIR recommendation.
The review did, however, identify occasional use of OIR
Table 7 New evidence on the
OIR/AWR recommendation
provided at a review of the
guidance
For further information about
the TAs and CGs listed in this
table, visit the NICE website:
http://www.nice.org.uk/
ACD Appraisal Consultation





Determination, OIR only in
research, RCT randomized
controlled trial, TA technology
appraisal
Original Review Additional evidence provided for
the OIR/AWR indication?
Summary of change to OIR/AWR guidance





TA6 TA30 No additional evidence presented OIR amended
OIR recommendation for a more restricted
indication
TA16 TA89 Updated RCT data and new non-
RCT evidence
OIR unchanged
(Some amendments to types of evidence
required)
TA17 TA105 New evidence (RCTs) available OIR removed
Technology recommended
TA30 CG81 New evidence (RCT and registry
data) available
OIR removed
CG81 did not include the OIR indication in
the scope of the guideline






New RCT and registry data
available
AWR removed
Technologies recommended. A new OIR
recommendation for another use of the drugs
was in the ACD, but this was removed in the
FAD
TA37 TA137 No new evidence presented OIR removed
Technology recommended
TA51 TA97 New evidence
(RCT and non-RCT) available
OIR amended
OIR targeted to specific packages rather than
CCBT as a class
TA72 CG79 New evidence (RCTs) available OIR unchanged
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recommendations for technologies where the best available
evidence suggests that they may be cost effective: early
appraisals of liquid-based cytology for cervical cancer
screening and CCBT. In both of these cases, the imple-
mentation of routine use of the technologies in the NHS
could have required substantial infrastructure or training
requirements and possibly significant irreversible costs. In
both cases, the initial guidance recommended research in
the form of ‘pilot implementation projects’. In many cases,
the ICER considered most plausible by the Appraisal
Committee was not stated; this was more common for OIR
than for AWR recommendations. This could be as a result
of the need for reassurance that the technologies were cost
effective prior to issuing a recommendation that would lead
to routine provision of the technology (albeit with research
required).
NICE has recently issued a categorization of all of its
TA guidance [29]. There are some differences between the
NICE categorization and the results of this review owing to
differences in the definitions employed. The most notable
differences relate to the classification of AWR guidance.
NICE does not use the terminology of AWR in its classi-
fication system. However, this review has identified a small
number of appraisals that apparently fall into this category
of approving a technology for use, and also recommending
research within the guidance to the NHS. In all of these
cases, observational studies and/or data collection through
disease registers were recommended and the technologies
were considered to be cost effective in most cases. The
NICE categorization only refers to final guidance. Of the
four pieces of final AWR guidance identified in this review,
NICE categorized one as recommended, two as ‘optimized’
and one as OIR. The lack of a formal category of AWR
recommendations by NICE most likely reflects its remit,
which is to make recommendations on the best use of
technologies within the NHS rather than to make recom-
mendations on research to research funders. Despite that,
there is clearly ambiguity in the terminology used in the
guidance and differences in the interpretation of recom-
mendations for research made within the Guidance sections
of the documents.
One striking finding from this review is the decline in the
use of OIR/AWR recommendations over the past 5 years.
The decline in the use of OIR/AWR recommendations
coincides with the introduction of the STA process in 2006
[30, 31]. Only one appraisal conducted through this pro-
cess—which is now the most commonly used process for
new technologies—included an OIR recommendation in the
final guidance and no STA appraisals included AWR rec-
ommendations. At first glance, this may appear counter-
intuitive. Technologies appraised through this process are
usually new and therefore have a more limited evidence
base than technologies appraised through the MTA process.
However, it could also be that the STA process has started
to shift the burden of the proof of effectiveness and cost
effectiveness onto the manufacturers and sponsors of
technologies. Recommendations to the NHS regarding the
research of these technologies may then be seen as less
relevant. The infrequency of OIR/AWR recommendations
within STA guidance could also reflect tighter time and
resource constraints in the production of STA guidance.
The rarity of OIR/AWR recommendations in the STA
process does not fully account for the reduction in the use
of OIR/AWR recommendations over time and there has
also been a decline in their use within the MTA process.
This decline could also be linked to an increased oppor-
tunity to negotiate on the costs of technologies through
PASs; however, there was no evidence of this based on the
review and there are usually no specific research require-
ments within PASs considered by NICE. There have been
several other changes to the NICE process within the
period covered by this review including the introduction
and update of two important documents underpinning the
NICE appraisals: NICE’s Guide to Methods of Technology
Appraisal in 2004 [32] and 2008 [9] and NICE’s Social
Value Judgements in 2005 [33] and 2008 [10]. It is difficult
to assess the direct impact of these documents as a delayed
impact following their introduction is likely. There has,
however, been no explicit policy change recorded in these
documents or elsewhere to explain the decline in OIR/
AWR recommendations. It is possible that with increasing
experience NICE has found OIR/AWR recommendations
to be less useful or the lack of a formal link to funders and
funding for these recommendations has created difficulty in
their implementation. It may also have been that with
experience NICE has found itself to have insufficient time
resources and expertise to adequately develop and priori-
tize research recommendations within its guidance.
A recent paper reporting a consensus statement devel-
oped by a group of academics and some policy makers
from Australia, Canada, the UK and the USA on the use of
coverage with evidence development recommended that
any such guidance should clearly specify the objective of
the recommendation and that this should inform the design
of the evidence development, which should also be clearly
specified [34]. It also recommended that the design of the
evidence development should clearly reflect the healthcare
system and its objectives, and that the governance for the
research should be independent of vested interests [34].
Whilst these aims are to be applauded, they do not appear
to have been widely implemented as yet and no direct
formal policy changes in the HTA or reimbursement
agencies have been reported (although it is noted that a
review of NICE methods in the UK is ongoing). The
review presented here has found that the use of OIR/AWR
recommendations by NICE meets some of these objectives
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but still has a way to go. The broad type of research
required was usually specified as was the rationale that led
to the decision. However, detailed research design
requirements and recommendations as to research gover-
nance were rarely specified. This likely reflects the lack of
a formal process for developing and funding NICE OIR/
AWR recommendations.
There have been a few recent developments at NICE,
which have increased the potential for further research
alongside approval, although their impact remains to be
proven. One opportunity has arisen through the supple-
mentary guidance to NICE Committees about technologies
used to treat patients at the end of life [35]. This guidance
describes criteria for when the Committees should consider
departing from the usual criteria for cost effectiveness. In
addition, the guidance states that when recommending a
treatment under the end-of-life criteria:
[NICE] will normally recommend to the Department
of Health that it should give consideration to a data
collection exercise for treatment recommended for
use on the basis of the criteria set out in section 2.
The purpose of this will be to assess the extent to
which the anticipated survival gains are evident when
the treatments involved are used in routine practice.
The outcome of this exercise will be evaluated when
the guidance for that treatment is reviewed. [35]
However, in practice the uptake of this recommendation
appears to be limited, and in an early review of the policy,
it was noted that implementation of such schemes had
proven problematic and was likely to be particularly
difficult for non-cancer treatments [36]. The second
opportunity has arisen through the introduction of PASs
in 2009. However, whilst these allow for additional data
collection, it is not a formal requirement for all schemes,
and most PASs agreed since the process was formally
established have been based on reducing the cost of
treatment, for example through simple price discounts or
rebates for some specified cycles of therapy [12], and such
schemes are frequently designed around only reducing the
costs of treatment. Finally, NICE has recently issued a
guide to assist the production of all of its research
recommendations, including those not forming part of the
mandatory guidance [11]. It states that relationships with
key funders of research in the UK are now integral within
the NICE processes and that NICE is proactively exploring
other further relationships. If this succeeds, it could
potentially enhance the use and implementation of OIR/
AWR guidance in the future, but it is currently too early to
judge.
A limitation of this analysis has been the reliance on the
documented considerations of the Appraisal Committee in
formulating its recommendations and whether these, in
some cases fairly brief, summaries fully reflect all the
considerations that led to the recommendations including
the recommendations for OIR/AWR. In addition, identifi-
cation of the ICERs considered most plausible by the
Committee was not always possible; the ICERs for the
specific OIR/AWR indications were frequently unclear or
unavailable from the documentation. However, the clarity
of reporting of the ICERs accepted by the Committee
appears to have improved over recent years. Finally,
focusing on the reviews as an indication of the success of
the OIR/AWR recommendations could bias towards a
positive finding as a lack of new evidence could have led to
the postponement of planned reviews. However, informa-
tion from the NICE website suggests that research to
potentially inform a review is being conducted in most of
the appraisals including OIR/AWR recommendations [29].
Sixteen OIR/AWR appraisals have been considered for
review: six have been postponed pending the reporting of
ongoing research and a further six are ongoing or sched-
uled. Only two reviews have been cancelled due to the lack
of new evidence and a further two cancelled due to the
technology becoming obsolete. Although this review has
focused on the TA programme within NICE, the types of
considerations in its other guidance programmes are likely
to be similar. Further research could examine this empiri-
cally within NICE or between other reimbursement
agencies.
5 Conclusions
This review has revealed that NICE has used OIR/AWR
recommendations since its inception, but these recom-
mendations appear to be on the decline. As a proportion of
guidance issued, the use of OIR/AWR recommendations
has been more common for appraisals of procedures and
devices than for pharmaceuticals. The most commonly
cited reason for issuing OIR/AWR guidance has been a
need for further evidence on the relative clinical effec-
tiveness of the technology, either for the licensed popula-
tion or for a subgroup. Consideration of cost effectiveness
is routine within the appraisal process, and OIR guidance
has mostly been issued for technologies that have not been
considered to be cost effective based on the evidence
available at the time of the appraisal. The potential impact
of a routine approval recommendation on ongoing research
or incurring irrecoverable costs does not appear to have
explicitly led to any OIR/AWR recommendations. This
review has highlighted the characteristics of technologies
that are more likely to receive OIR or AWR recommen-
dations, particularly with regard to the cost effectiveness;
uncertainty in relative effectiveness; and uncertainty about
long-term effects or adverse events. The development of a
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formal policy on the types of considerations that lead to
OIR/AWR recommendations at NICE could improve the
transparency and predictability of decision making.
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